Alvotech
ALVO • NASDAQ
Alvotech is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Vilhelm Robert Wessman, with a market cap of $969.1M.
CEOVilhelm Robert Wessman
Market Cap$969.1M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees999.0
Websitealvotech.com
Next Earnings
Upcoming earnings announcement for Alvotech
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.01
Revenue Estimate
$139.0M
Earnings History
Past 12 earnings reports for Alvotech
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Q4 2025 | -$0.37Est: $0.05 | -840.0% | $168.9MEst: $159.2M | +6.1% | — |
| Nov 12, 2025 | Q3 2025 | -$0.02Est: $0.02 | -200.0% | $113.7MEst: $122.8M | -7.4% | — |
| Aug 13, 2025 | Q2 2025 | $0.14Est: -$0.11 | +227.3% | $173.2MEst: $118.4M | +46.4% | — |
| May 7, 2025 | Q1 2025 | $0.35Est: $0.42 | -16.7% | $132.8MEst: $163.3M | -18.7% | — |
| Mar 26, 2025 | Q4 2024 | —Est: -$0.47 | — | —Est: $87.9M | — | — |
| Nov 13, 2024 | Q3 2024 | -$0.02Est: -$0.06 | +66.7% | $102.9MEst: $89.0M | +15.6% | — |
| Aug 15, 2024 | Q2 2024 | $0.28Est: $0.00 | — | $198.7MEst: $199.0M | -0.1% | — |
| May 21, 2024 | Q1 2024 | -$0.89Est: -$0.08 | -1012.5% | $36.9M | — | — |
| Mar 20, 2024 | Q4 2023 | -$1.22 | — | $53.4M | — | — |
| Nov 28, 2023 | Q3 2023 | -$0.82 | — | $17.8M | — | — |
| Aug 30, 2023 | Q2 2023 | $0.85 | — | $6.9M | — | — |
| May 19, 2023 | Q1 2023 | -$1.24 | — | $15.9M | — | — |